Andere Kunden interessierten sich auch für
![CD38 AS A PROGNOSTIC FACTOR IN B-CELL CHRONIC LYMPHOCYTIC LEUKAEMIA]( "CD38 AS A PROGNOSTIC FACTOR IN B-CELL CHRONIC LYMPHOCYTIC LEUKAEMIA")
CD38 AS A PROGNOSTIC FACTOR IN B-CELL CHRONIC LYMPHOCYTIC LEUKAEMIA48,99 €![Chronic Myeloid Leukemia]( "Chronic Myeloid Leukemia")
Chronic Myeloid Leukemia65,99 €![Chronic Myeloid Leukemia]( "Chronic Myeloid Leukemia")
Chronic Myeloid Leukemia89,99 €![Chronic Myeloid Leukemia]( "Chronic Myeloid Leukemia")
Chronic Myeloid Leukemia97,99 €![TURA classification in chronic myeloid leukemia]( "TURA classification in chronic myeloid leukemia")
TURA classification in chronic myeloid leukemia44,99 €![The bipolarity of Chronic stress:from immunodeficiency to autoimmunity]( "The bipolarity of Chronic stress:from immunodeficiency to autoimmunity")
The bipolarity of Chronic stress:from immunodeficiency to autoimmunity39,99 €![QUININE AND ARTEMETHER IN THE TREATMENT OF SEVERE MALARIA IN CHILDREN]( "QUININE AND ARTEMETHER IN THE TREATMENT OF SEVERE MALARIA IN CHILDREN")
QUININE AND ARTEMETHER IN THE TREATMENT OF SEVERE MALARIA IN CHILDREN35,99 €
Imatinib mesylate is a novel drug which targets the molecular level in chronic myeloid leukaemia. The response rates in various studies were very impressive. There is no study of efficacy and adverse effects of imatinib mesylate in our local patients. It is generally believed that these would be similar to that of Western patients. However, physical and genetic differences may influence the effects of imatinib mesylate in Asian patients.